BMS-986482 + bevacizumab

BMS-986482 + bevacizumab is an investigational oral combination therapy currently in clinical trials for the treatment of advanced solid tumors. BMS-986482 is a small molecule inhibitor of tyrosine kinase 2 (TYK2), designed to block inflammatory and immune-related signaling pathways implicated in cancer progression, while bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A) to inhibit tumor angiogenesis. The combination aims to leverage immune modulation (via TYK2 inhibition) and anti-angiogenesis (via VEGF inhibition) to enhance antitumor efficacy. The combination is being developed by Bristol-Myers Squibb and is under evaluation for safety, tolerability, pharmacokinetics, and preliminary antitumor activity in patients with various advanced solid malignancies, including but not limited to lung, breast, colorectal, and melanoma cancers[1][2][4][6][8].